Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019

Executive Summary

With the first generic versions of blockbuster brands like Advair, Lyrica, Restasis and Sensipar and the first biosimilars of Herceptin, Avastin and Rituxan expected to launch in the US, 2019 could be a notable year for generics and biosimilars.
Advertisement

Related Content

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis
Cipla, Piramal Launch Sensipar Generics Amid Growing Antitrust Challenges to Amgen/Teva Settlement
Generic Sensipar: Cipla Challenges Legality of Amgen/Teva Patent Settlement
Pfizer: Time To Face The Lyrica Pain
Keeping Track: FDA's Review Actions Carry On During Shutdown
Keeping Track: US FDA Receives Submissions Galore As Year Ends
Novartis Gives Up On Rituxan Biosimilar For US Market
Mylan Clears Runway For US Herceptin Biosimilar Launch

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124915

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel